Immunome, Inc.
IMNM
$18.13
-$0.26-1.41%
NASDAQ
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -8.64% | 3.21% | |||
| Gross Profit | 8.64% | -3.21% | |||
| SG&A Expenses | 7.10% | 10.47% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -5.62% | 4.53% | |||
| Operating Income | 5.62% | -4.53% | |||
| Income Before Tax | 22.98% | -21.66% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 22.98% | -21.66% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 22.98% | -21.66% | |||
| EBIT | 5.62% | -4.53% | |||
| EBITDA | 5.63% | -4.51% | |||
| EPS Basic | 35.37% | -12.72% | |||
| Normalized Basic EPS | 24.59% | 3.40% | |||
| EPS Diluted | 35.37% | -12.72% | |||
| Normalized Diluted EPS | 24.59% | 3.40% | |||
| Average Basic Shares Outstanding | 19.18% | 7.93% | |||
| Average Diluted Shares Outstanding | 19.18% | 7.93% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||